Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133781 · ClinicalTrials.gov registry record · Phase 4
B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
A Phase 4 study of Influenza, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT02133781 is a Phase 4 study of Influenza that has completed, run by Stanford University. The registered enrollment target is 51 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02133781, a Phase 4 study of Influenza, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an exploratory study using a strategy that has not been previously employed to investigate the effects of age and vaccine type on specific kinds of immune responses to licensed, seasonal 2009-2010 influenza vaccines in children and adults.
Conditions Studied
Interventions
- BIOLOGICAL Fluzone® 2009-2010 Formula
- BIOLOGICAL FluMist® 2009-2010 Formula
Study Locations (1)
California
- Stanford LPCH Vaccine Program - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02133781
The ClinicalTrials.gov registry entry for NCT02133781 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Fluzone® 2009-2010 Formula is the first listed.
NCT02133781 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02133781 about?
NCT02133781 is a clinical study titled "B-cell Immunity to Influenza (SLVP017)- Year 1, 2009". This is an exploratory study using a strategy that has not been previously employed to investigate the effects of age and vaccine type on specific kinds of immune responses to licensed, seasonal 2009-2010 influenza vaccines in children and adults.
What is the current status of trial NCT02133781?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2009-07. Estimated completion is 2009-12.
What conditions does trial NCT02133781 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT02133781?
The interventions under investigation include: Fluzone® 2009-2010 Formula (BIOLOGICAL), FluMist® 2009-2010 Formula (BIOLOGICAL).
Who is sponsoring clinical trial NCT02133781?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02133781 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Bone Marrow and Peripheral Blood Immune Responses Study
RECRUITING · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
COMPLETED · Phase 4
-
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
COMPLETED · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.